The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Israel

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 2 · randomised · 1,109 people · 47 sites in 8 countries · Recruiting now

August 7, 2026
Safety of HRX215 in Patients After Minor and Major Liver Resection

Phase 2 · randomised · 80 people · 12 sites in 5 countries · Recruiting now

August 7, 2026
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Phase 2 · randomised · 390 people · 59 sites in 14 countries · Recruiting now

August 7, 2026
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 · randomised · 800 people · 285 sites in 17 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now

August 7, 2026
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer

Phase 3 · randomised · 477 people · 223 sites in 29 countries · Recruiting now

August 7, 2026